Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Gains from Investment Securities (2016 - 2024)

Historic Gains from Investment Securities for NovaBay Pharmaceuticals (NBY) over the last 14 years, with Q2 2024 value amounting to $80000.0.

  • NovaBay Pharmaceuticals' Gains from Investment Securities rose 13703.7% to $80000.0 in Q2 2024 from the same period last year, while for Mar 2025 it was $80000.0, marking a year-over-year increase of 11716.74%. This contributed to the annual value of -$114000.0 for FY2024, which is 5808.82% up from last year.
  • As of Q2 2024, NovaBay Pharmaceuticals' Gains from Investment Securities stood at $80000.0, which was up 13703.7% from -$194000.0 recorded in Q1 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Gains from Investment Securities peaked at $3.8 million during Q2 2020, and registered a low of -$4.6 million during Q4 2021.
  • Its 5-year average for Gains from Investment Securities is -$435916.7, with a median of -$165500.0 in 2020.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 37710000.0% in 2020, then tumbled by 5758750.0% in 2021.
  • Over the past 5 years, NovaBay Pharmaceuticals' Gains from Investment Securities (Quarter) stood at -$8000.0 in 2020, then crashed by 57587.5% to -$4.6 million in 2021, then skyrocketed by 78.85% to -$976000.0 in 2022, then soared by 94.26% to -$56000.0 in 2023, then skyrocketed by 242.86% to $80000.0 in 2024.
  • Its last three reported values are $80000.0 in Q2 2024, -$194000.0 for Q1 2024, and -$56000.0 during Q4 2023.